Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer.

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Activating mutations in the ERBB2 gene (HER2), such as exon 20 insertions, are found in 2-4% of lung adenocarcinomas.
• Limited therapeutic options exist for patients with these HER2-mutant lung cancers.

Purpose of the Study:

• To evaluate the preclinical and clinical activity of sevabertinib, a dual EGFR-HER2 inhibitor, in lung cancer models with HER2 alterations.
• To assess the potential of sevabertinib as a treatment for HER2-mutant lung cancer.

Main Methods:

• Testing sevabertinib in preclinical lung cancer models with various HER2 alterations (exon 20 insertions, point mutations, amplification).
• Evaluating sevabertinib's activity in a cell line dependent on neuregulin-1/HER3 signaling.
• Analyzing patient responses from a phase 1/2 clinical trial of sevabertinib.

Main Results:

• Sevabertinib demonstrated potent preclinical activity against lung cancer models harboring HER2 exon 20 insertions and other HER2 alterations.
• The drug showed efficacy in a cell line dependent on neuregulin-1/HER3 signaling.
• Early clinical data from a phase 1/2 trial indicated potential patient benefit.

Conclusions:

• Sevabertinib is a potent dual EGFR-HER2 inhibitor with selective activity against wild-type EGFR.
• Preclinical and early clinical data suggest sevabertinib is a promising therapeutic option for patients with HER2-mutant lung cancer, including those with exon 20 insertions.